Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$3.00 USD
-0.32 (-9.52%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $2.99 -0.01 (-0.17%) 4:34 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZNTL 3.00 -0.32(-9.52%)
Will ZNTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZNTL
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
Other News for ZNTL
Zentalis Pharmaceuticals GAAP EPS of -$1.24
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
Zentalis sees cash runway into mid-2026
Zentalis CMO Diana Hausman steps down
Zentalis discontinuing development of ZN-d5